{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-25-000017","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2025-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.333692+00:00","generated_at":"2026-05-27T03:46:23.472579+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pfizer Q4/FY2024 rev $63.6B (+7% op); adj EPS $3.11; reaffirms 2025 guidance","bullets":["FY2024 revenues $63.6B (+7% operational); excluding COVID products, up 12% operationally.","FY2024 reported diluted EPS $1.41; adjusted diluted EPS $3.11. Q4 adjusted EPS $0.63.","Reaffirms FY2025 guidance: revenue $61-$64B, adjusted diluted EPS $2.80-$3.00.","On track for ~$4.5B net cost savings by end 2025; $1.5B from Manufacturing Optimization by 2027.","Positive Phase 3 BREAKWATER for Braftovi in mCRC; sold ~$3B Haleon stake; Boshoff named CSO."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-25-000017","json":"https://secwatch.observer/filing/0000078003-25-000017.json","markdown":"https://secwatch.observer/filing/0000078003-25-000017.md","text":"https://secwatch.observer/filing/0000078003-25-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000017/0000078003-25-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000017/pfe-20250204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T03:46:23.472579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}